US2018127507A1PendingUtilityA1

Methods of treating progressive forms of multiple sclerosis

45
Assignee: ABBVIE BIOTHERAPEUTICS INCPriority: Aug 8, 2011Filed: Nov 6, 2017Published: May 10, 2018
Est. expiryAug 8, 2031(~5 yrs left)· nominal 20-yr term from priority
Inventors:Steven GreenbergJacob Stephen Broomall Elkins
C07K 16/2866C07K 2317/94A61K 2039/54A61K 2039/505C07K 2317/24C07K 2317/732C07K 2317/92A61K 2039/545A61P 25/00
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to methods of treating individuals suffering from progressive forms of multiple sclerosis.

Claims

exact text as granted — not AI-modified
1 . A method of treating a human subject suffering from a progressive form of multiple sclerosis, comprising subcutaneously administering to the subject about 150 mg to about 300 mg of a daclizumab once every four weeks for a period of at least one year. 
     
     
         2 - 11 . (canceled)

Join the waitlist — get patent alerts

Track US2018127507A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.